Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Dysplasia 1

Interventions

GX-188 vaccine 4human papillomavirus vaccine, L1 type 16, 18 3Human Papillomavirus DNA Tests 3Colposcopy 3Blood Specimen Collection 3Vaccines 2VGX-3100 2Topotecan 2Restraint, Physical 2Paclitaxel 2Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 2Cisplatin 2Biopsy 25-aminolevulinic acid hexyl ester 24,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone 2terameprocol 1poly(gamma-glutamic acid) 1poly ICLC 1methyl 5-aminolevulinate 1epigallocatechin gallate 1artesunic acid 1artemisinin 1ZYC101a 1Watchful Waiting 1Vaccines, Synthetic 1Transurethral Resection of Prostate 1Pregnancy Tests 1Pemetrexed 1Papillomavirus Vaccines 1Ointments 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Uterine Cervical Dysplasia × Mutagenesis, Insertional × Clear all
NCT05502367 2026-02-19

A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Intraepithelial Neoplasia

Antiva Biosciences

Phase 1/2 Terminated
44 enrolled
Gynecologic

Uterine Cervical Dysplasia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡